Renin inhibition reduces atherosclerotic plaque neovessel formation and regresses advanced atherosclerotic plaques

Atherosclerosis

Volumn 237, Issue 2, 2014, Pages 739e747-747

  Wu, Hongxian ^a   Cheng, Xian Wu ^a,c   Hu, Lina ^a   Hao, Chang Ning ^a   Hayashi, Mutsuharu ^a   Takeshita, Kyosuke ^a   Hamrah, Mohammad Shoaib ^a   Shi, Guo Ping ^b   Kuzuya, Masafumi ^a   Murohara, Toyoaki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c YANBIAN UNIVERSITY   (China)

Author keywords

Aliskiren; Angiotensin II; Atherosclerosis; Cathepsin S; Toll like receptor 2

Indexed keywords

ALISKIREN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; CATHEPSIN S; COLLAGEN; ELASTIN; HYDRALAZINE; MONOCYTE CHEMOTACTIC PROTEIN 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; RENIN; TOLL LIKE RECEPTOR 2;

ANGIOTENSIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ROOT; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE REGULATION; CAT; CELL INFILTRATION; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME INHIBITION; EX VIVO STUDY; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; MACROPHAGE ACTIVATION; MACROPHAGE MIGRATION; MOUSE; NEOINTIMA; NONHUMAN; PROTEIN EXPRESSION; TREATMENT OUTCOME;

EID: 84910641174     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.10.098     Document Type: Article

References (30)

1. Daugherty A., Cassis L. Angiotensin II-mediated development of vascular diseases. Trends Cardiovasc. Med. 2004, 14:117-120.
2. Lu H., Rateri D.L., Feldman D.L., Charnigo R.J., Fukamizu A., Ishida J.J., et al. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J.Clin. Investig. 2008, 118:984-993.
3. Imanishi T., Tsujioka H., Ikejima H., Kuroi A., Takarada S., Kitabata H., et al. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Hypertension 2008, 52:563-572.
4. Weber C., Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat. Med. 2011, 17:1410-1422.
5. Edfeldt K., Swedenborg J., Hansson G.K., Yan Z.Q. Expression of toll-like receptors in human atherosclerotic lesions - a possible pathway for plaque activation. Circulation 2002, 105:1158-1161.
6. Michelsen K.S., Wong M.H., Shah P.K., Zhang W.X., Yano J.A., Doherty T.M., et al. Lack of toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:10679-10684.
7. Liu X., Ukai T., Yurnoto H., Davey M., Goswami S., Gibson F.C., et al. Toll-like receptor 2 plays a critical role in the progression of atherosclerosis that is independent of dietary lipids. Atherosclerosis 2008, 196:146-154.
8. Cheng X.W., Song H.Z., Sasaki T., Hu L.N., Inoue A., Bando Y.K., et al. Angiotensin type 1 receptor blocker reduces intimal neovascularization and plaque growth in apolipoprotein e-deficient mice. Hypertension 2011, 57. 981-U238.
9. Moulton K.S., Heller E., Konerding M.A., Flynn E., Palinski W., Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 1999, 99:1726-1732.
10. Celletti F.L., Waugh J.M., Amabile P.G., Brendolan A., Hilfiker P.R., Dake M.D. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat. Med. 2001, 7:425-429.
11. Cheng X.W., Huang Z., Kuzuya M., Okumura K., Murohara T. Cysteine protease cathepsins in atherosclerosis-based vascular disease and its complications. Hypertension 2011, 58:978-986.
12. Egami K., Murohara T., Shimada T., Sasaki K., Shintani S., Sugaya T., et al. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J.Clin. Investig. 2003, 112:67-75.
13. Hu L., Cheng X.W., Song H., Inoue A., Jiang H., Li X., et al. Cathepsin K activity controls injury-related vascular repair in mice. Hypertension 2014, 63:607-615.
14. Cheng X.W., Shi G.P., Kuzuya M., Sasaki T., Okumura K., Murohara T. Role for cysteine protease cathepsins in heart disease focus on biology and mechanisms with clinical implication. Circulation 2012, 125:1551-1562.
15. Jiang H., Cheng X.W., Shi G.P., Hu L., Inoue A., Yamamura Y., et al. Cathepsin K-mediated notch1 activation contributes to neovascularization in response to hypoxia. Nat. Commun. 2014, 5:3838.
16. Shi G.P., Sukhova G.K., Kuzuya M., Ye Q., Du J., Zhang Y., et al. Deficiency of the cysteine protease cathepsin s impairs microvessel growth. Circ. Res. 2003, 92:493-500.
17. Wang B., Sun J.S., Kitamoto S., Yang M., Grubb A., Chapman H.A., et al. Cathepsin s controls angiogenesis and tumor growth via matrix-derived angiogenic factors. J.Biol. Chem. 2006, 281:6020-6029.
18. Kuzuya M., Nakamura K., Sasaki T., Cheng X.W., Itohara S., Iguchi A. Effect of MMP-2 deficiency on atherosclerotic lesion formation in apoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2006, 26:1120-1125.
19. Matsumoto M., Sata M., Fukuda D., Tanaka K., Soma M., Hirata Y., Nagai R. Orally administered eicosapentaenoic acid reduces and stabilizes atherosclerotic lesions in apoE-deficient mice. Atherosclerosis 2008, 197:524-533.
20. Cheng X.W., Kuzuya M., Kim W., Song H.Z., Hu L.N., Inoue A., et al. Exercise training stimulates ischemia-induced neovascularization via phosphatidylinositol 3-kinase/Akt-dependent hypoxia-induced factor-1 alpha reactivation in mice of advanced age. Circulation 2010, 122:707-716.
21. Cheng X.W., Kuzuya M., Nakamura K., Maeda K., Tsuzuki M., Kim W., et al. Mechanisms underlying the impairment of ischemia-induced neovascularization in matrix metalloproteinase 2-deficient mice. Circ. Res. 2007, 100:904-913.
22. Sukhova G.K., Zhang Y., Pan J.H., Wada Y., Yamamoto T., Naito M., et al. Deficiency of cathepsin s reduces atherosclerosis in LDL receptor-deficient mice. J.Clin. Investig. 2003, 111:897-906.
23. Sasaki T., Kuzuya M., Nakamura K., Cheng X.W., Hayashi T., Song H.Z., et al. At1 blockade attenuates atherosclerotic plaque destabilization accompanied by the suppression of cathepsin s activity in apoE-deficient mice. Atherosclerosis 2010, 210:430-437.
24. Ji Y.Y., Liu J.T., Wang Z.D., Liu N. Angiotensin II induces inflammatory response partly via toll-like receptor 4-dependent signaling pathway in vascular smooth muscle cells. Cell Physiol. Biochem. 2009, 23:265-276.
25. Ahn K.O., Lim S.W., Li C., Yang H.J., Ghee J.Y., Kim J.Y., et al. Influence of angiotensin II on expression of toll-like receptor 2 and maturation of dendritic cells in chronic cyclosporine nephropathy. Transplantation 2007, 83:938-947.
26. Trinchieri G., Sher A. Cooperation of toll-like receptor signals in innate immune defence. Nat. Rev. Immunol. 2007, 7:179-190.
27. Monaco C., Gregan S.M., Navin T.J., Foxwell B.M.J., Davies A.H., Feldmann M. Toll-like receptor-2 mediates inflammation and matrix degradation in human atherosclerosis. Circulation 2009, 120:2462-2469.
28. Rodgers K.J., Watkins D.J., Miller A.L., Chan P.Y., Karanam S., Brissette W.H., et al. Destabilizing role of cathepsin s in murine atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol. 2006, 26:851-856.
29. Moreno P.R., Purushothaman R., Fuster V., Echeverri D., Truszczynska H., Sharma S.K., et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta - implications for plaque vulnerability. Circulation 2004, 110:2032-2038.
30. Sun Y., Ishibashi M., Seimon T., Lee M., Sharma S.M., Fitzgerald K.A., et al. Free cholesterol accumulation in macrophage membranes activates toll-like receptors and p38 mitogen-activated protein kinase and induces cathepsin K. Circ. Res. 2009, 104. 455-U475.